Posts With Tag respiratory diseases

Explore AstraZeneca's latest Form 6-K detailing Tezspire's FDA approval for CRSwNP, clinical trial successes, and market impact. Discover its potential in chronic respiratory care.

AstraZeneca's 6-K filing reveals the RESOLUTE Phase III trial results for Fasenra in COPD. The treatment showed numerical improvements but did not meet primary endpoint significance.